This report describes a case which successfully treated with rituximab against autoimmune hemolytic anemia caused by both warm autoantibodies and cold agglutinin (mixed AIHA). A 52-year-old man with malaise was referred to our hospital in December 2002. A diagnosis of mixed AIHA was made. His clinical course showed that the hemolysis was mainly caused by cold agglutinin, with a possible contribution from the warm autoantibody. He was treated with prednisolone (PSL), Cyclosporine (CyA), and cyclophosphamide (CPA). The treatment with PSL, CyA, and CPA failed to stabilize the hemolysis caused by cold exposure in the winter season. In November 2013 (winter season), rituximab therapy (375 mg/m2 weekly for four weeks) was started, and the hemolysis improved. The present case suggests that rituximab is useful against mixed AIHA. Further studies are warranted to establish the effectiveness of rituximab against mixed AIHA.
| Published in | American Journal of Internal Medicine (Volume 3, Issue 4) |
| DOI | 10.11648/j.ajim.20150304.12 |
| Page(s) | 156-159 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Autoimmune Hemolytic Anemia, Rituximab, Mixed Autoimmune Hemolytic Anemia
| [1] | S. Bluml, K. McKeever, R. Ettinger, J. Smolen and R. Herbst. B-cell targeted therapeutics in clinical development. Arthritis Res Ther. 2013; 15 Suppl 1: S4. |
| [2] | K. Lechner and U. Jager. How I treat autoimmune hemolytic anemias in adults. Blood. 2010; 116(11): 1831-8. |
| [3] | G. Bussone, E. Ribeiro, A. Dechartres, J. F. Viallard, B. Bonnotte, O. Fain, B. Godeau and M. Michel. Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases. Am J Hematol. 2009; 84(3): 153-7. |
| [4] | S. Berentsen, E. Ulvestad, B. T. Gjertsen, H. Hjorth-Hansen, R. Langholm, H. Knutsen, W. Ghanima, F. V. Shammas and G. E. Tjonnfjord. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004; 103(8): 2925-8. |
| [5] | C. E. Brown, J. P. Traynor, R. A. Sharp and J. G. Fox. Successful treatment with rituximab of autoimmune haemolytic anaemia causing dialysis-dependent acute renal failure. Nephrol Dial Transplant. 2007; 22(9): 2730-1. |
| [6] | D. Webster, B. Ritchie and M. J. Mant. Prompt response to rituximab of severe hemolytic anemia with both cold and warm autoantibodies. Am J Hematol. 2004; 75(4): 258-9. |
| [7] | K. Ono, T. Sato, S. Iyama, A. Tatekoshi, A. Hashimoto, Y. Kamihara, H. Horiguchi, S. Kikuchi, K. Takada, T. Hayashi, K. Miyanishi, Y. Sato, R. Takimoto, M. Kobune and J. Kato. Successful treatment with rituximab in a patient with refractory mixed-type autoimmune hemolytic anemia [Japanese article]. Rinsho Ketsueki. 2013; 54(11): 2053-5. |
| [8] | S. Gupta, A. Szerszen, F. Nakhl, S. Varma, A. Gottesman, F. Forte and M. Dhar. Severe refractory autoimmune hemolytic anemia with both warm and cold autoantibodies that responded completely to a single cycle of rituximab: a case report. J Med Case Rep. 2011; 5: 156. |
| [9] | M. Morselli, M. Luppi, L. Potenza, S. Tonelli, D. Dini, G. Leonardi, A. Donelli, F. Narni and G. Torelli. Mixed warm and cold autoimmune hemolytic anemia: complete recovery after 2 courses of rituximab treatment. Blood. 2002; 99(9): 3478-9. |
APA Style
Motoharu Shibusawa, Yoshirou Murai, Hisashi Tsutsumi. (2015). Successful Rituximab Treatment of Autoimmune Hemolytic Anemia Caused by Both Warm Autoantibodies and Cold Agglutinin: A Case Report. American Journal of Internal Medicine, 3(4), 156-159. https://doi.org/10.11648/j.ajim.20150304.12
ACS Style
Motoharu Shibusawa; Yoshirou Murai; Hisashi Tsutsumi. Successful Rituximab Treatment of Autoimmune Hemolytic Anemia Caused by Both Warm Autoantibodies and Cold Agglutinin: A Case Report. Am. J. Intern. Med. 2015, 3(4), 156-159. doi: 10.11648/j.ajim.20150304.12
AMA Style
Motoharu Shibusawa, Yoshirou Murai, Hisashi Tsutsumi. Successful Rituximab Treatment of Autoimmune Hemolytic Anemia Caused by Both Warm Autoantibodies and Cold Agglutinin: A Case Report. Am J Intern Med. 2015;3(4):156-159. doi: 10.11648/j.ajim.20150304.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajim.20150304.12,
author = {Motoharu Shibusawa and Yoshirou Murai and Hisashi Tsutsumi},
title = {Successful Rituximab Treatment of Autoimmune Hemolytic Anemia Caused by Both Warm Autoantibodies and Cold Agglutinin: A Case Report},
journal = {American Journal of Internal Medicine},
volume = {3},
number = {4},
pages = {156-159},
doi = {10.11648/j.ajim.20150304.12},
url = {https://doi.org/10.11648/j.ajim.20150304.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20150304.12},
abstract = {This report describes a case which successfully treated with rituximab against autoimmune hemolytic anemia caused by both warm autoantibodies and cold agglutinin (mixed AIHA). A 52-year-old man with malaise was referred to our hospital in December 2002. A diagnosis of mixed AIHA was made. His clinical course showed that the hemolysis was mainly caused by cold agglutinin, with a possible contribution from the warm autoantibody. He was treated with prednisolone (PSL), Cyclosporine (CyA), and cyclophosphamide (CPA). The treatment with PSL, CyA, and CPA failed to stabilize the hemolysis caused by cold exposure in the winter season. In November 2013 (winter season), rituximab therapy (375 mg/m2 weekly for four weeks) was started, and the hemolysis improved. The present case suggests that rituximab is useful against mixed AIHA. Further studies are warranted to establish the effectiveness of rituximab against mixed AIHA.},
year = {2015}
}
TY - JOUR T1 - Successful Rituximab Treatment of Autoimmune Hemolytic Anemia Caused by Both Warm Autoantibodies and Cold Agglutinin: A Case Report AU - Motoharu Shibusawa AU - Yoshirou Murai AU - Hisashi Tsutsumi Y1 - 2015/06/23 PY - 2015 N1 - https://doi.org/10.11648/j.ajim.20150304.12 DO - 10.11648/j.ajim.20150304.12 T2 - American Journal of Internal Medicine JF - American Journal of Internal Medicine JO - American Journal of Internal Medicine SP - 156 EP - 159 PB - Science Publishing Group SN - 2330-4324 UR - https://doi.org/10.11648/j.ajim.20150304.12 AB - This report describes a case which successfully treated with rituximab against autoimmune hemolytic anemia caused by both warm autoantibodies and cold agglutinin (mixed AIHA). A 52-year-old man with malaise was referred to our hospital in December 2002. A diagnosis of mixed AIHA was made. His clinical course showed that the hemolysis was mainly caused by cold agglutinin, with a possible contribution from the warm autoantibody. He was treated with prednisolone (PSL), Cyclosporine (CyA), and cyclophosphamide (CPA). The treatment with PSL, CyA, and CPA failed to stabilize the hemolysis caused by cold exposure in the winter season. In November 2013 (winter season), rituximab therapy (375 mg/m2 weekly for four weeks) was started, and the hemolysis improved. The present case suggests that rituximab is useful against mixed AIHA. Further studies are warranted to establish the effectiveness of rituximab against mixed AIHA. VL - 3 IS - 4 ER -
Information
Email: